Status:
RECRUITING
The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease
Lead Sponsor:
Chujin Cao
Conditions:
CKD
Drug Effect
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Chronic kidney disease (CKD) has become a major public health problem worldwide. Patients with CKD are often accompanied by azotemia due to impaired renal function and excretion of nitrogen metabolic ...
Eligibility Criteria
Inclusion
- Written informed consent was obtained;
- ranging in age from 18 to 75 years;
- CKD stage 3-5, that is, eGFR \< 60 mL/min/1.73 m2 with non-dialysis stage, no dialysis indication, temporarily stable condition and drug control stage;
- tolerance of Xiqing and probiotics treatment.
Exclusion
- with severe active infection, influence of nutritional status in patients with malignant tumor and other diseases;
- patients during pregnancy or lactation;
- unstable vital signs, the condition is not stable, need dialysis patients;
- patients with intolerance of Xiqing;
- patients with intolerance of probiotics;
- taking corticosteroids, antibiotics or other immunosuppressive agents within the past 3 months;
- taking adsorbent drugs, such as medicinal charcoal tablets, within the past 3 months.
Key Trial Info
Start Date :
June 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07182942
Start Date
June 7 2024
End Date
December 31 2025
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030